Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]

6 reported adverse events

Drugs of this class: TEBENTAFUSP

These side effects are most commonly reported by patients taking drugs of the Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] class:

# Side effect Count
0 CYTOKINE RELEASE SYNDROME 3
1 FATIGUE 2
2 HYPOTENSION 2
3 ACUTE MYELOID LEUKAEMIA 1
4 ALANINE AMINOTRANSFERASE INCREASED 1
5 ASPARTATE AMINOTRANSFERASE INCREASED 1
6 ASYMPTOMATIC COVID-19 1
7 BLOOD ALKALINE PHOSPHATASE INCREASED 1
8 DECREASED APPETITE 1
9 DIARRHOEA 1
See all common reactions for Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]

Drugs of the Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ASYMPTOMATIC COVID-19 1 0.0040
1 PROTHROMBIN LEVEL INCREASED 1 0.0035
2 CYTOKINE RELEASE SYNDROME 3 0.0005
3 LEUKAEMIA 1 0.0001
4 TACHYPNOEA 1 0.0001
5 ACUTE MYELOID LEUKAEMIA 1 0.0001
6 RASH MACULO-PAPULAR 1 0.0001
7 BLOOD ALKALINE PHOSPHATASE INCREASED 1 0.0000
8 INTERNATIONAL NORMALISED RATIO INCREASED 1 0.0000
9 OXYGEN SATURATION DECREASED 1 0.0000
See all enriched reactions for Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]